Tuberculosis (TB) is the main reason behind infectious mortality on this planet, affecting primarily creating nations (DC), whereas diabetes (DM) is likely one of the most prevalent persistent illnesses. This evaluation analyzes the truth that diabetes is at the moment an essential threat issue for creating TB, additionally presenting extra sophisticated TB, extra relapses and better mortality.
The DCs and the fourth world of the big cities are these with the best incidence of TB and a rise in DM, which can make it troublesome to manage tuberculosis illness. On the identical time, the COVID-19 pandemic is complicating the administration of each illnesses as a result of issue of entry to manage and remedy and the worsening of socioeconomic inequalities.
It’s vital to determine a bidirectional screening for TB and DM and promote suggestions for the joint administration of each illnesses. The necessity for instructional interventions on pure natural remedies and to suggest the combination of natural medication into present medical techniques is beneficial.
The impression of several types of psychological problems on long-term glycemic and lipid trajectories following newly identified sort 2 diabetes (T2D) stays unknown. We used real-world scientific information in a population-based cohort to fill this data hole.
We discovered that people with new T2D and preexisting character, anxiousness, unipolar despair, or psychotic dysfunction had greater imply HbA1c ranges over Four years following the onset of T2D, whereas no variations had been discovered concerning LDL-C ranges. This information ought to be thought of within the administration of T2D in these susceptible teams. Diabetes and tuberculosis: A syndemic complicated by COVID-19

Experiences of Sufferers on Pure Natural Therapies for Diabetes Mellitus on the Diabetes Clinic in Base Hospital – Matara, Sri Lanka

The prevalence of diabetes mellitus has turn out to be a world public well being problem. Pure natural remedies for sort 2 diabetes mellitus have been broadly utilized in conventional societies however has just lately turn out to be widespread amongst western societies as effectively. The goal of this research was to discover the expertise of sort 2 sufferers with diabetes mellitus who’re at the moment on pure natural remedy.

A qualitative, phenomenological design has been used. Twelve individuals from each women and men, aged between 25 and 75 years, who had been on medical remedy, had been chosen for sampling. In-depth interviews had been performed on the diabetes clinic in a particular hospital in southern Sri Lanka.

The athematic evaluation was performed, and 6 themes had been derived. The vast majority of individuals (75%) had been motivated to make use of pure natural remedies apart from oral glycemic remedy. Experiences have been recognized as probably the most influential elements in the usage of pure natural remedies.

Charges of osteoporosis analysis and administration after main fragility fractures have remained low in recent times. The extent to which this remedy hole impacts sufferers with diabetes is unclear. This research aimed to match the danger of secondary fractures and charges of osteoporosis prognosis and administration after sentinel fractures in sufferers with and with out diabetes.

A propensity score-matched cohort research was performed utilizing the PearlDiver database. Sufferers aged 50 years and older with main fragility fractures of the hip, wrist, backbone, pelvis, humerus, and different places had been recognized.

Charges of secondary fractures, twin radiograph absorptiometry (DXA) scans, charted osteoporosis diagnoses (Worldwide Classification of Ailments, Ninth and Tenth Revisions), and osteoporosis pharmacotherapy inside 2 years had been in contrast for sufferers with and with out diabetes utilizing multivariable logistic regression.

Inhibitory impact of tumor necrosis factor-α on the basolateral Kir4.1/Kir5.1 channels within the thick ascending limb throughout diabetes

Diabetic nephropathy is a significant contributor to the morbidity and mortality of sufferers with diabetes. TNF-α expression is elevated throughout diabetes and is implicated within the pathogenesis of diabetic nephropathy; nonetheless, its underlying molecular mechanisms stay unclear.

The current research aimed to analyze the impact and molecular mechanism of TNF-α on the basolateral inwardly rectifying potassium (Kir)4.1/Kir5.1 channels within the thick ascending limb (TAL) of rat kidneys utilizing western blotting and the patch clamp approach to supply a theoretical foundation for the reason for the lower in kidney concentrating capability throughout diabetes.

The outcomes demonstrated that urinary TNF-α excretion and protein TNF-α expression within the TAL elevated and basolateral Kir4.1/Kir5.1 channel exercise decreased throughout diabetes; nonetheless, diabetic rats exhibited amelioration of Kir4.1/Kir5.1 exercise with a soluble TNF-α antagonist, TNF receptor fusion protein (TNFR:Fc).

These outcomes prompt that TNF-α inhibited the exercise of the basolateral Kir4.1/Kir5.1 channel within the TAL of rat kidneys throughout diabetes. As well as, the protein expression ranges of phospholipase A2 (PLA2) and cyclooxygenase-2 (COX2) elevated in diabetic rats, the results of which deceased following remedy with TNFR:Fc in contrast with the diabetic group.

Moreover, an agonist of PLA2 (melittin) and COX2 manufacturing [prostaglandin E2 (PGE2)] inhibited the basolateral Kir4.1/Kir5.1 channels. Taken collectively, the outcomes of the current research prompt that the inhibitory impact of TNF-α on the basolateral Kir4.1/Kir5.1 channels within the TAL throughout diabetes is mediated by the PLA2/COX2/PGE2 signaling pathway.

Administration of sort 1 diabetes mellitus utilizing open-source automated insulin supply throughout being pregnant: a case collection

Ladies with sort 1 diabetes (T1D) want to attain tight glycemic management throughout being pregnant to be able to keep away from hostile obstetric and perinatal outcomes. Targets for time in vary (TIR) of >70% [63-140 mg/dL], time beneath vary (TBR) of <5 % and time above vary (TAR) of <25% are beneficial.

We report on 4 pregnancies of girls with T1D who determined to make use of open-source automated insulin supply techniques to handle their diabetes. Knowledge was collected retrospectively from the medical data and Nightscout documentation.Besides the primary trimester of case 3, TIR was >70 % all through all pregnancies.

Gene Knock-Out HR Targeting Vector [MCS1-EF1a-GFP-T2A-Puro-pA-MCS2]
HR410PA-1 10 ug
EUR 1023
  • Category: HR Donors

Gene Knock-Out HR Targeting Vector [MCS1-EF1a-RFP-T2A-Hygro-pA-MCS2]
HR510PA-1 10 ug
EUR 1023
  • Category: HR Donors

TARGATT? Knock-in iPSC Generation (Master Cell Line)
AST-1100 1 vial of 1X10^6 cells Ask for price
Description: 6 month

TARGATT? Knock-in Mouse Cell Line Generation Kit (Master Cell Line)
AST-7001 1 Kit Ask for price
Description: 6 month

Rrad 3'UTR GFP Stable Cell Line
TU168183 1.0 ml Ask for price

RRAD 3'UTR Luciferase Stable Cell Line
TU022380 1.0 ml
EUR 1394

Rrad 3'UTR Luciferase Stable Cell Line
TU118183 1.0 ml Ask for price

RRAD 3'UTR GFP Stable Cell Line
TU072380 1.0 ml
EUR 1394

Rrad 3'UTR Luciferase Stable Cell Line
TU219725 1.0 ml Ask for price

Rrad 3'UTR GFP Stable Cell Line
TU269725 1.0 ml Ask for price

HEK-293T cells
T0011002 One Frozen vial
EUR 455

TARGATT? Knock-in CHO Generation Kit (Master Cell Line)
AST-1200 1 Kit Ask for price
Description: 12 month

TARGATT? Knock-in HEK293 Generation Kit (Master Cell Line)
AST-1300 1 Kit Ask for price
Description: 12 month

Rrad/ Rat Rrad ELISA Kit
ELI-14921r 96 Tests
EUR 886

HEK-293T Telomerase Over-Expressing Cell Pellet
abx069991-1Pellet 1 Pellet
EUR 398
  • Shipped within 1-3 working days.

Basic HR Targeting Vector [MCS1-LoxP-MCS2-MCS3-pA-LoxP-MCS4] for Gene Knock-In/Out
HR100PA-1 10 ug
EUR 938
  • Category: HR Donors

RRAD antibody
70R-50359 100 ul
EUR 244
Description: Purified Polyclonal RRAD antibody

RRAD antibody
70R-5797 50 ug
EUR 467
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD

RRAD antibody
70R-5798 50 ug
EUR 467
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD

RRAD Antibody
37229-100ul 100ul
EUR 252

RRAD siRNA
20-abx932133
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol
  • Shipped within 5-10 working days.

RRAD Antibody
1-CSB-PA003910
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000

RRAD Antibody
1-CSB-PA779820
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
  • Form: Liquid
  • Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

RRAD Antibody
1-CSB-PA248209
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
  • Form: Liquid
  • Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100

RRAD Antibody
CSB-PA233809-
EUR 335
  • Form: liquid
  • Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
  • Show more
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500

RRAD Antibody
CSB-PA233809-100ul 100ul
EUR 316
  • Form: liquid
  • Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
  • Show more
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500

293AD Cell Line
AD-100 1 vial
EUR 461
Description: The 293AD Cell Line is derived from the parental 293 cells but selected for attributes that increase adenovirus production, including firmer attachment and larger surface area.

293AAV Cell Line
AAV-100 1 vial
EUR 508
Description: The 293AAV Cell Line is derived from the parental 293 cells but selected for attributes that increase AAV production, including firmer attachment and larger surface area.

293LTV Cell Line
LTV-100 1 vial
EUR 508
Description: The 293LTV Cell Line is derived from the parental 293 cells but selected for attributes that increase lentiviral production, including fimrer attachment and larger surface area.

293RTV Cell Line
RV-100 1 vial
EUR 508
Description: The 293RTV Cell Line is derived from the parental 293 cells but selected for attributes that increase retroviral production, including fimrer attachment and larger surface area.

RRAD sgRNA CRISPR Lentivector set (Human)
K2069901 3 x 1.0 ug
EUR 339

RRAD ELISA KIT|Human
EF005507 96 Tests
EUR 689

Human RRAD shRNA Plasmid
20-abx954199
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg
  • Shipped within 15-20 working days.

RRAD Recombinant Protein (Human)
RP095493 100 ug Ask for price

Microplate Swing-Out Centrifuge
abx725026-1Unit 1 Unit
EUR 1476
  • Shipped within 10-15 working days.

Clinical Swing-Out Centrifuge
abx725027-1Unit 1 Unit
EUR 1476
  • Shipped within 10-15 working days.

Gene Knock-Out HR Targeting Vector w/Single Selection Marker (Blasticidin) and Negative Selection (TK) Against Random Integration
HR720PA-1 10 µg
EUR 1145
  • Category: HR Donors

293T Transfection Kit (1 mL)
P902 NULL
EUR 0

293T Transfection Kit (0.2 mL)
P902S NULL
EUR 0

293T Transfection Kit (1 mL)
P903 NULL
EUR 0

293T Transfection Kit (0.2 mL)
P903S NULL
EUR 0

293/GFP Cell Line
AKR-200 1 vial
EUR 572
Description: 293/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

T47D/GFP Cell Line
AKR-208 1 vial
EUR 572
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

A549/GFP Cell Line
AKR-209 1 vial
EUR 572
Description: A549/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

HeLa/GFP Cell Line
AKR-213 1 vial
EUR 572
Description: HeLa/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

NIH3T3/GFP Cell Line
AKR-214 1 vial
EUR 572
Description: NIH3T3/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

NIH3T3/Cas9 Cell Line
AKR-5104 1 vial
EUR 572

293/Cas9 Cell Line
AKR-5110 1 vial
EUR 572

HeLa/Cas9 Cell Line
AKR-5111 1 vial
EUR 572

RRAD Conjugated Antibody
C37229 100ul
EUR 397

Polyclonal RRAD Antibody
APR05556G 0.1ml
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human RRAD . This antibody is tested and proven to work in the following applications:

RRAD Blocking Peptide
20-abx063234
  • EUR 272.00
  • EUR 411.00
  • 1 mg
  • 5 mg
  • Shipped within 5-10 working days.

RRAD Blocking Peptide
33R-4793 100 ug
EUR 180
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5797

RRAD Blocking Peptide
33R-10070 100 ug
EUR 180
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798

Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (GFP+Puro) and Negative Selection (TK) Against Random Integration
HR700PA-1 10 µg
EUR 1145
  • Category: HR Donors

Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (RFP+Hygro) and Negative Selection (TK) Against Random Integration
HR710PA-1 10 µg
EUR 1145
  • Category: HR Donors

RRAD sgRNA CRISPR Lentivector (Human) (Target 1)
K2069902 1.0 ug DNA
EUR 154

RRAD sgRNA CRISPR Lentivector (Human) (Target 2)
K2069903 1.0 ug DNA
EUR 154

RRAD sgRNA CRISPR Lentivector (Human) (Target 3)
K2069904 1.0 ug DNA
EUR 154

SKOV-3/Luc Cell Line
AKR-232 1 vial
EUR 572
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line.

MCF-7/Luc Cell Line
AKR-234 1 vial
EUR 572
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line.

OVCAR-5/RFP Cell Line
AKR-254 1 vial
EUR 572
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line.

RRAD ORF Vector (Human) (pORF)
ORF031832 1.0 ug DNA
EUR 405

Gene Knock-Out HR Targeting Vector with TK selection [MCS1-LoxP-EF1?-GFP-T2A-Puro-P2A-hsvTK-pA-LoxP-MCS2]
HR210PA-1 10 ug
EUR 1145
  • Category: HR Donors

Rrad sgRNA CRISPR Lentivector set (Mouse)
K3480701 3 x 1.0 ug
EUR 339

Rrad sgRNA CRISPR Lentivector set (Rat)
K7052701 3 x 1.0 ug
EUR 339

RRAD Recombinant Protein (Rat)
RP226925 100 ug Ask for price

RRAD Recombinant Protein (Mouse)
RP169340 100 ug Ask for price

Platinum-E Retroviral Packaging Cell Line, Ecotropic
RV-101 1 vial
EUR 920
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-E cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection.

Platinum-A Retroviral Packaging Cell Line, Amphotropic
RV-102 1 vial
EUR 920
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-A cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection.

Platinum-GP Retroviral Packaging Cell Line, Pantropic
RV-103 1 vial
EUR 920
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-GP cells contain the gag and pol genes required for retroviral packaging; an expression vector is co-transfected with a VSVG envelope vector.

TARGATT? Knock-in iPSC Genotyping Kit
AST-1102 1 Kit Ask for price
Description: 12 month

PinPoint-FC 293T Platform Cell Line for Targeted Gene Insertion (with PinPoint site already placed)
PIN320A-1 >2x10^5 cells
EUR 3104
  • Category: PinPoint Integrase Tools

Total Protein - Murine Embryonic Stem Cell Line D3
CBA-305 500 ?g
EUR 345
Description:
  • Isolated from mouse ES-D3 cell line
  • Presented as 500 µg at 1 mg/mL in NP-40 Solubilization Buffer

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 1)
K3480702 1.0 ug DNA
EUR 154

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 2)
K3480703 1.0 ug DNA
EUR 154

Rrad sgRNA CRISPR Lentivector (Mouse) (Target 3)
K3480704 1.0 ug DNA
EUR 154

Rrad sgRNA CRISPR Lentivector (Rat) (Target 1)
K7052702 1.0 ug DNA
EUR 154

Rrad sgRNA CRISPR Lentivector (Rat) (Target 2)
K7052703 1.0 ug DNA
EUR 154

Rrad sgRNA CRISPR Lentivector (Rat) (Target 3)
K7052704 1.0 ug DNA
EUR 154

TARGATT? Knock-in iPSC Quick Knockin Kit
AST-1101 1 Kit Ask for price
Description: 12 month

Rrad ORF Vector (Mouse) (pORF)
ORF056448 1.0 ug DNA
EUR 506

Rrad ORF Vector (Rat) (pORF)
ORF075643 1.0 ug DNA
EUR 506

Anti-RRAD (aa36-48) antibody
STJ72757 100 µg
EUR 359

RRAD Protein Vector (Human) (pPB-C-His)
PV127326 500 ng
EUR 552

RRAD Protein Vector (Human) (pPB-N-His)
PV127327 500 ng
EUR 552

RRAD Protein Vector (Human) (pPM-C-HA)
PV127328 500 ng
EUR 552

RRAD Protein Vector (Human) (pPM-C-His)
PV127329 500 ng
EUR 552

Out At First Protein Homolog (OAF) Antibody
abx146027-100ug 100 ug
EUR 391
  • Shipped within 5-10 working days.

Out At First Protein Homolog (OAF) Antibody
abx027798-400ul 400 ul
EUR 523
  • Shipped within 5-10 working days.

Out At First Protein Homolog (OAF) Antibody
abx027798-80l 80 µl
EUR 286
  • Shipped within 5-10 working days.

HBS w/out Phenol Red, 500 ml
409 500 ml
EUR 72

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
K2069905 3 x 1.0 ug
EUR 376

GTP-Binding Protein RAD (RRAD) Antibody
20-abx008742
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul
  • Shipped within 5-10 working days.

GTP-binding protein RAD (RRAD) Antibody
20-abx324872
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug
  • Shipped within 5-10 working days.

GTP-binding protein RAD (RRAD) Antibody
20-abx214509
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

GTP-binding protein RAD (RRAD) Antibody
abx332370-100ul 100 ul
EUR 425
  • Shipped within 5-10 working days.

GTP-Binding Protein RAD (RRAD) Antibody
abx432011-200ul 200 ul
EUR 384
  • Shipped within 1-3 working days.

GTP-binding protein RAD (RRAD) Antibody
20-abx241706
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Human GTP- binding protein RAD, RRAD ELISA KIT
ELI-35549h 96 Tests
EUR 824

Human GTP-binding protein RAD (RRAD) ELISA Kit
abx385354-96tests 96 tests
EUR 911
  • Shipped within 5-12 working days.

Human OAF (Out at first protein homolog) ELISA Kit (CUSTOM)
ELI-38218h 96 Tests
EUR 824

EtB Out Nucleic Acid Staining Solution20,000 x RoomTemperature
FYD007-200P 200 Preps, 1 ml Ask for price

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)
K2069906 1.0 ug DNA
EUR 167

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)
K2069907 1.0 ug DNA
EUR 167

RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)
K2069908 1.0 ug DNA
EUR 167

CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric
CBA-135 96 assays
EUR 821
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.

CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric
CBA-135-5 5 x 96 assays
EUR 3356
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.

CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Fluorometric
CBA-140 96 assays
EUR 856
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.

CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Fluorometric
CBA-140-5 5 x 96 assays
EUR 3483
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.

StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible)
CBA-325 96 assays
EUR 856
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis.

StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible)
CBA-325-5 5 x 96 assays
EUR 3361
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis.

Polyclonal RRAD (aa36-48) Antibody (internal region)
APG00807G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human RRAD (aa36-48) (internal region). This antibody is tested and proven to work in the following applications:

RRAD Protein Vector (Rat) (pPB-C-His)
PV302570 500 ng
EUR 603

RRAD Protein Vector (Rat) (pPB-N-His)
PV302571 500 ng
EUR 603

RRAD Protein Vector (Rat) (pPM-C-HA)
PV302572 500 ng
EUR 603

RRAD Protein Vector (Rat) (pPM-C-His)
PV302573 500 ng
EUR 603

RRAD Protein Vector (Mouse) (pPB-C-His)
PV225790 500 ng
EUR 603

RRAD Protein Vector (Mouse) (pPB-N-His)
PV225791 500 ng
EUR 603

RRAD Protein Vector (Mouse) (pPM-C-HA)
PV225792 500 ng
EUR 603

RRAD Protein Vector (Mouse) (pPM-C-His)
PV225793 500 ng
EUR 603

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
K3480705 3 x 1.0 ug
EUR 376

Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)
K7052705 3 x 1.0 ug
EUR 376

Chicken Out at first protein homolog, oaf ELISA KIT
ELI-13285c 96 Tests
EUR 928

Rat Out at first protein homolog, Oaf ELISA KIT
ELI-15146r 96 Tests
EUR 886

Mouse Out at first protein homolog (OAF) ELISA Kit
abx390101-96tests 96 tests
EUR 911
  • Shipped within 5-12 working days.

Rat Out at first protein homolog (OAF) ELISA Kit
abx391739-96tests 96 tests
EUR 911
  • Shipped within 5-12 working days.

Two caesarean sections had been required; two ladies had a vaginal supply. Beginning weight was regular (2), small (1) and huge (1) for gestational age. We noticed wonderful glycemic management when utilizing open-source automated insulin supply in 4 T1D pregnancies.

RELATED ARTICLESMORE FROM AUTHOR

LEAVE A REPLY

Please enter your comment!
Please enter your name here